Results 81 to 90 of about 529 (145)

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma. [PDF]

Clin Cancer Res
Aggen DH, McKean M, Hoffman-Censits JH, Lakhani NJ, Alhalabi O, Guancial EA, Bashir B, Bowman IA, Tan A, Lingaraj T, Ortiz-Otero N, Bartolini W, Timothy M, Kim K, Kacena K, Santillana S, Luke JJ.   +16 more
europepmc   +1 more source

Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics. [PDF]

Cancer Med
Ören Varol T, Varol M.
europepmc   +1 more source

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. [PDF]

Cell Rep Med, 2023
Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, Zhou Y, Wang W, Xia D, Wang ZM, Li B, Xia M, Desai J.   +12 more
europepmc   +1 more source

First-in-human study of the dual A₂_A/A₂_B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. [PDF]

ESMO Open
Siu LL, Gutierrez ME, Pudelko L, Ruth K, Filho MAFN, Zaynagetdinov R, Hu P, Kitzing T, Guenhan BK, Durutovic I, McKean M.   +10 more
europepmc   +1 more source

Crossing the finish line towards a disease-modifying treatment for Angelman syndrome. [PDF]

J Neurodev Disord
Judson MC, de Almeida LP, Burdine RD, Chamberlain SJ, Deverman BE, Distel B, Ehlers MD, Jalazo E, Kushner SA, Nespeca M, Sanders SJ, Scheffner M, Yi JJ, Zylka MJ, Elgersma Y, Philpot BD.   +15 more
europepmc   +1 more source

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600-Mutant Advanced Melanoma. [PDF]

J Clin Oncol
Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R.   +24 more
europepmc   +1 more source

PD-1 Targeted Antibody Discovery Using AI Protein Diffusion. [PDF]

Technol Cancer Res Treat
Ford CT.
europepmc   +1 more source

First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. [PDF]

ESMO Open
Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK.   +9 more
europepmc   +1 more source

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. [PDF]

Curr Oncol
Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S.   +18 more
europepmc   +1 more source

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. [PDF]

Br J Cancer, 2023
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J.   +13 more
europepmc   +1 more source